The Pericapsular Nerve Block in Total Hip Arthroplasty

Launched by LIFEBRIDGE HEALTH · Jan 27, 2021

Keywords

ClinConnect Summary

This clinical trial is studying a new way to manage pain after total hip replacement surgery, specifically comparing two types of nerve blocks: the pericapsular nerve block and the fascia iliaca nerve block. The goal is to find out which method is more effective in helping patients feel comfortable after surgery, making it easier for them to recover and potentially go home the same day.

To participate in this study, you need to be between 18 and 75 years old, have plans for a specific type of hip surgery, and not be currently using opioids for pain relief. Participants will need to sign a consent form and agree to follow the study procedures throughout the trial. It's important to note that patients with chronic pain conditions or those who have been on certain pain medications may not qualify. If you join the study, you can expect close monitoring and support to see how well the nerve block works for your pain management after surgery.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Provision of signed and dated informed consent form
• • Stated willingness to comply with all study procedures and availability for the duration of the study
• • Planned primary total hip arthroplasty with anterior (Smith-Peterson) approach
• • ASA score of 1 to 3
• • Indicated for one of the two nerve block groups
• • Must be opioid naïve at screening as defined by the FDA - According to the Food and Drug Administration, opioid-tolerant patients were those currently receiving or who had previously received 60 mg PO morphine per day, 25 mcg transdermal fentanyl per hour, 30 mg PO oxycodone per day, 8 mg PO hydromorphone per day, 25 mg PO oxymorphone per day, 60 mg PO hydrocodone per day, or an equivalent dose of another opioid for a duration of one week or longer (16)
• Exclusion Criteria:
• • Current or previous diagnosis of "chronic pain"
• • Opioid tolerant at time of screening (for a week or longer, at least 60 mg of morphine daily, or at least 30 mg of oral oxycodone daily, or at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid.)
• • Diagnosis of ankylosing spondylitis
• • Allergy to any potential medications utilized in any of the two groups
• • Conversion of patient to general anesthesia intraoperatively
• • Treatment with another investigational drug or other intervention for pain
• • Any condition(s) or diagnosis, both physical or psychological, or physical exam finding in the opinion of the investigator that would precludes participation